“Our drugs do not work on most patients.” Such did Allen Roses, then worldwide vice-president of genetics at GlaxoSmithKline, greet his audience, during a scientific meeting in London in 2003.1 Nearly a decade has passed since then, and significant strides towards the development of genotype-guided prescribing have been made. Pharmacogenetics and pharmacogenomics are now an established area of pharmacology specialization, and they hold the promise of the key to personalized medicine, leading to safer and more effective patientfocussed therapeutic outcomes.peer-reviewe
